ERIN DUVALL: Open Payments
NPI 1003254087 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$66,628 in 148 payments from 12 companies in 2025. Trend: 2023 $75,902 · 2024 $60,973 · 2025 $66,628
Speaker / faculty: $59,519Travel & lodging: $4,759Food & beverage: $2,350
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 80 | $44,535 |
| Otsuka America Pharmaceutical, Inc. | 38 | $14,412 |
| Vanda Pharmaceuticals Inc. | 17 | $7,318 |
| Teva Pharmaceuticals USA, Inc. | 2 | $140 |
| Janssen Pharmaceuticals, Inc | 3 | $54 |
| Lundbeck LLC | 2 | $43 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Hologic Sales and Service, LLC | 1 | $24 |
| Theratechnologies Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: VRAYLAR, ABILIFY MAINTENA, FANAPT, REXULTI, UZEDY, ABILIFY ASIMTUFII, SPRAVATO, INGREZZA.
Industry payments across MO — which companies pay providers there.
